PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|June 10, 2020
LaunchWorks Manufacturing Lab is Now LaunchWorks CDMO
Author(s)Pharmaceutical Technology Editors
The news comes after the company received its FDA registered ISO 13485 as a CDMO.
Advertisement
LaunchWorks Manufacturing Lab, a life sciences company, announced on June 8, 2020 that it is now LaunchWorks CDMO (contract development and manufacturing organization).
The news comes after the company received its FDA registered ISO 13485 as a CDMO, a press release said. Integron Global, a packaging solutions provider, acquired Launchworks in 2017 and has since added additional service offerings, including an automation program. Most recently, the company has responded to the COVID-19 pandemic.
“The enhancement of our services is an important step in showcasing our commitment to deliver a comprehensive scope of capabilities, to support our clients’ path to commercialization. Our service offerings are designed to meet each customer’s unique set of challenges,” said Jeff Kelly, general manager of LaunchWorks CDMO, in the press release. “This is a crucial step as we expand our ability to support the world’s changing needs due to the pandemic as well as incorporate automation and device manufacturing. Launchworks, with our service suite ranging from package design to fulfillment and technologies, is uniquely positioned to meet the challenge of helping companies translate their science into commercial products, thereby contributing to the improvement in world health.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement